Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Inflammatory Bowel Disease IV: Pharmacological Management

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Osimertinib-Associated Benign Ocular Hyperpigmentation: A Case Report.

Cornea·2026

Same author

The variable neuropsychological profile of Diets-Jongmans syndrome: a case series of four family members.

Archives of clinical neuropsychology : the official journal of the National Academy of Neuropsychologists·2026

Same author

A Randomized Double-Masked Study Evaluating Safety and Efficacy of a Novel Topical Cooling Device for Chronic Ocular Surface Pain.

Ophthalmology and therapy·2026

Same author

Implantation of Small-Aperture IOL in Patients with Cataract and Preexisting Corneal Comorbidities.

Clinical ophthalmology (Auckland, N.Z.)·2026

Same author

Comparison of immunity-boosting regimens for COVID-19 upon initiation of immunosuppressive therapy (CIRCUIT): study protocol for a randomised, controlled clinical trial.

BMJ open·2026

Same author

Trial of an Internet-Based Cataract and Lens Exchange Registry in a Tertiary Teaching Hospital: Insights and Impact on Clinical Workflow.

Journal of ophthalmology·2026

Search research articles

Related Experiment Video

Updated: Jul 15, 2025

Author Spotlight: Advancing Corneal Innervation Research Through Innovative Models

Author Spotlight: Advancing Corneal Innervation Research Through Innovative Models

Published on: December 8, 2023

Biologics in peripheral ulcerative keratitis.

Daniel Clarke¹, Lauren Sartor², Vu Do³

¹Department of Ophthalmology, Royal Hobart Hospital, Tasmania, Australia; Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.

Seminars in Arthritis and Rheumatism

|September 30, 2023

Summary

This summary is machine-generated.

Biologic therapies, including rituximab, show promise for treating severe peripheral ulcerative keratitis (PUK). While evidence is limited, these treatments offer an effective option for refractory cases, particularly those linked to autoimmune diseases.

Keywords:

Biologics Granulomatous with polyangiitis Peripheral ulcerative keratitis Rituximab

More Related Videos

Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats

Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats

Published on: May 23, 2025

Adenoviral Gene Therapy for Diabetic Keratopathy: Effects on Wound Healing and Stem Cell Marker Expression in Human Organ-cultured Corneas and Limbal Epithelial Cells

Adenoviral Gene Therapy for Diabetic Keratopathy: Effects on Wound Healing and Stem Cell Marker Expression in Human Organ-cultured Corneas and Limbal Epithelial Cells

Published on: April 7, 2016

Related Experiment Videos

Last Updated: Jul 15, 2025

Author Spotlight: Advancing Corneal Innervation Research Through Innovative Models

Author Spotlight: Advancing Corneal Innervation Research Through Innovative Models

Published on: December 8, 2023

Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats

Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats

Published on: May 23, 2025

Adenoviral Gene Therapy for Diabetic Keratopathy: Effects on Wound Healing and Stem Cell Marker Expression in Human Organ-cultured Corneas and Limbal Epithelial Cells

Adenoviral Gene Therapy for Diabetic Keratopathy: Effects on Wound Healing and Stem Cell Marker Expression in Human Organ-cultured Corneas and Limbal Epithelial Cells

Published on: April 7, 2016

Area of Science:

Ophthalmology
Rheumatology
Immunology

Background:

Biologic therapies have become crucial in managing ocular inflammation over the last 20 years.
Peripheral ulcerative keratitis (PUK) is a severe ocular condition often associated with systemic rheumatological diseases.
Historically, PUK posed a significant risk of blindness and mortality, but newer treatments are emerging.

Purpose of the Study:

To review the existing evidence for using biologic therapies in managing peripheral ulcerative keratitis (PUK).
To provide guidance on the clinical application, including dosage and adverse effects, of biologics for PUK.
To assess the efficacy of biologics in refractory cases of PUK.

Main Methods:

A comprehensive literature search was conducted across major databases: Medline, Embase, and Cochrane Database of Systematic Reviews.
The search focused on identifying peer-reviewed articles detailing the treatment of PUK patients with biologic agents.
Case reports and series were analyzed to gather data on treatment outcomes and adverse events.

Main Results:

The overall evidence base for biologic use in PUK is currently limited.
However, reported cases indicate that biologics are increasingly effective in managing refractory PUK.
Rituximab demonstrated particular efficacy in PUK secondary to granulomatous with polyangiitis.

Conclusions:

Biologic therapies represent a powerful and effective treatment option for patients with refractory PUK.
Further research is needed to strengthen the evidence base, but current data support their use.
Clinical guidelines for the use of biologics in PUK are emerging, with specific considerations for agents like rituximab.